• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

ABX-464 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759118

ABX-464 is a potent anti-HIV agent. ABX464 inhibits HIV-1 replication in stimulated peripheral blood mononuclear cells (PBMCs) (IC50 : 0.1uM - 0.5uM) More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
ABX-464, Inhibitor
Full Product Name
ABX-464
Product Gene Name
Product Synonym Names
ABX464
Form/Format
Solid. Powder
Purity/Purification
100.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
338.71
Solubility
DMSO: 100mg/mL (295.24mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C16H10ClF3N2O
SMILES
FC(F)(F)Oc1ccc(Nc2ccc3cccc(Cl)c3n2)cc1
CAS Number
1258453-75-6
Target & IC50
HIV-1: ic50 0.1uM-0.5uM
In Vitro
ABX464 represents a novel class of anti-HIV molecules with unique properties. ABX464 has a long lasting effect in humanized mice and neutralizes the expression of HIV-1 proviral genome of infected immune cells including reservoirs and it is therefore a promising drug toward a functional cure of HIV[1].

Structure of ABX-464, inhibitor

ABX-464 Inhibitor – Cat# MBS5759118

Product References and Citations for ABX-464, inhibitor

Campos N, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. Retrovirology. 2015 Apr 9;12:30.
Campos N, et al. Long lasting control of viral rebound with a new drug ABX464 targeting Rev-mediated viral RNA biogenesis. Retrovirology. 2015 Apr 9;12:30.
Didier S, Regine R, Noel B P, et al. Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects[J]. Journal of Antimicrobial Chemotherapy(3):3.
Didier S, Regine R, Noel B P, et al. Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects[J]. Journal of Antimicrobial Chemotherapy(3):3.

Other Notes

Small volumes of ABX-464, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for ABX-464 purchase

MBS5759118 is an inhibitor targeting ABX-464.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000